Laboratory for Cardio-Immunology

Led by Kai-Uwe Jarr, M.D.

Soluble TWEAK is markedly upregulated in patients with ST-elevation myocardial infarction and related to an adverse short-term outcome.


Journal article


E. Chorianopoulos, K. Jarr, H. Steen, E. Giannitsis, N. Frey, H. Katus
Atherosclerosis, 2010

Semantic Scholar DOI PubMed
Cite

Cite

APA   Click to copy
Chorianopoulos, E., Jarr, K., Steen, H., Giannitsis, E., Frey, N., & Katus, H. (2010). Soluble TWEAK is markedly upregulated in patients with ST-elevation myocardial infarction and related to an adverse short-term outcome. Atherosclerosis.


Chicago/Turabian   Click to copy
Chorianopoulos, E., K. Jarr, H. Steen, E. Giannitsis, N. Frey, and H. Katus. “Soluble TWEAK Is Markedly Upregulated in Patients with ST-Elevation Myocardial Infarction and Related to an Adverse Short-Term Outcome.” Atherosclerosis (2010).


MLA   Click to copy
Chorianopoulos, E., et al. “Soluble TWEAK Is Markedly Upregulated in Patients with ST-Elevation Myocardial Infarction and Related to an Adverse Short-Term Outcome.” Atherosclerosis, 2010.


BibTeX   Click to copy

@article{e2010a,
  title = {Soluble TWEAK is markedly upregulated in patients with ST-elevation myocardial infarction and related to an adverse short-term outcome.},
  year = {2010},
  journal = {Atherosclerosis},
  author = {Chorianopoulos, E. and Jarr, K. and Steen, H. and Giannitsis, E. and Frey, N. and Katus, H.}
}